Industrial Chemistry
Open Access

Green Chemistry; Sustainability Benchmarks; Pharmaceutical Industry; Environmental Impact; Carbon Neutrality; Waste Reduction

Introduction

The pharmaceutical industry plays a critical role in global health, driving innovation in drug development, therapies, and vaccines. However, with this immense influence comes a substantial environmental footprint. From research and development (R&D) processes to large-scale manufacturing, the pharmaceutical sector is energy-intensive and often involves the use of hazardous chemicals [1,2]. This has spurred a global movement toward more environmentally conscious practices within the industry, with sustainability becoming a key strategic priority.

The environmental impact of pharmaceuticals

The environmental impact of pharmaceutical production is multifaceted, spanning resource depletion, greenhouse gas (GHG) emissions, water consumption, chemical waste, and even pharmaceutical contamination in natural ecosystems.

Energy consumption and emissions: The pharmaceutical industry is energy-intensive due to the complexity of chemical synthesis and biologic processes. This energy use results in substantial GHG emissions, which contribute to climate change [3,4]. According to some estimates, the pharmaceutical industry is more carbon-intensive than the automotive sector when adjusted for output.

Water pollution: Wastewater from pharmaceutical plants, containing active pharmaceutical ingredients (APIs), solvents, and other hazardous chemicals, is a significant concern. Residual drugs that pass through treatment plants can enter waterways, adversely affecting aquatic life. Moreover, the long-term impact of low-dose exposure to pharmaceuticals on ecosystems is still not fully understood [5].

Resource utilization and waste generation: Pharmaceutical manufacturing generates substantial amounts of waste, much of which is classified as hazardous. High water consumption in both the manufacturing and cooling processes further adds to the environmental burden. The excessive use of solvents, a key ingredient in pharmaceutical synthesis, is also concerning due to their toxicity and volatility[6,7].

Plastic and packaging waste: The sector is a significant contributor to global plastic waste due to the need for specialized packaging materials that maintain product stability and sterility. The resulting plastic waste exacerbates the already critical global issue of plastic pollution [8].

Green chemistry: The Foundation for Environmental Sustainability

A transformative approach to addressing these environmental challenges is the adoption of green chemistry principles. These principles, first articulated in the 1990s, aim to design chemical products and processes that reduce or eliminate the use and generation of hazardous substances. Green chemistry seeks to minimize environmental damage while maintaining or improving the effectiveness and efficiency of chemical processes.

Key principles of green chemistry that can be applied in the pharmaceutical sector include:

Atom Economy: This principle encourages the design of synthetic methods that maximize the incorporation of all materials used into the final product. By minimizing by-products and waste, atom economy helps reduce resource consumption and pollution [9,10].

Safer solvents and reagents: Traditional pharmaceutical processes often use toxic and volatile organic solvents. Green chemistry emphasizes the development of safer, more sustainable alternatives, including the use of water, supercritical CO₂, and bio-based solvents.

Energy efficiency: The pharmaceutical industry consumes a vast amount of energy. Green chemistry advocates for the development of processes that can be conducted at ambient temperatures and pressures, reducing the energy demand of chemical reactions.

Reduction of derivatives: Minimizing unnecessary steps in chemical synthesis—such as the use of protective groups can reduce waste and improve overall process efficiency.

Design for degradation: Another important green chemistry principle is to design chemicals and pharmaceuticals that can break down into harmless by-products after their useful life, reducing the long-term environmental impact of pharmaceutical residues.

Sustainable benchmarks in the pharmaceutical sector

In response to growing pressure from governments, regulatory agencies, investors, and consumers, many pharmaceutical companies have started setting ambitious sustainability benchmarks. These efforts are focused on minimizing environmental harm while still delivering high-quality medications. Some of the key benchmarks include

Carbon neutrality: Several pharmaceutical companies have set targets to achieve carbon neutrality. This includes minimizing emissions from operations and supply chains and offsetting remaining emissions through carbon credits or investments in renewable energy projects. For instance, companies like AstraZeneca and Johnson & Johnson have announced commitments to achieving net-zero carbon emissions by 2030 and 2045, respectively. Carbon neutrality often involves a multipronged strategy, including energy efficiency measures, increased use of renewable energy sources, carbon capture and storage technologies, and offsetting emissions through reforestation or other carbon capture projects.

Waste reduction: Pharmaceutical companies are working to reduce waste across all stages of the product life cycle. One key area of focus is the minimization of hazardous waste from chemical processes. Pfizer, for example, has implemented green chemistry principles that have reduced the volume of solvents and hazardous materials used in its manufacturing processes. Many companies are also exploring circular economy models, where waste materials are repurposed or recycled back into the production process. Another area of waste reduction is packaging. Many companies are working to reduce the amount of plastic used in pharmaceutical packaging and are exploring biodegradable or recyclable alternatives. This not only reduces environmental harm but also aligns with consumer demand for more sustainable products.

Water stewardship: As water scarcity becomes a growing global concern, pharmaceutical companies are implementing water stewardship programs aimed at reducing water consumption and improving water quality. Companies like Novartis have committed to using water responsibly and have set ambitious goals to reduce water withdrawals and achieve water neutrality in water-stressed regions. Water reuse and recycling systems are also being integrated into manufacturing plants to further reduce freshwater consumption.

Green supply chains: Sustainability in the pharmaceutical industry extends beyond production to the entire supply chain. Companies are working to create greener supply chains by selecting suppliers based on their environmental performance and encouraging sustainable practices across the board. For example, GlaxoSmithKline has established sustainability criteria for its suppliers, focusing on energy and water use, waste management, and the reduction of emissions and hazardous substances. Pharmaceutical companies are also striving to reduce the carbon footprint of their logistics operations by optimizing transportation routes, utilizing more fuel-efficient vehicles, and embracing digitalization to streamline supply chains.

Product life cycle assessments (LCAs): Conducting comprehensive life cycle assessments (LCAs) helps pharmaceutical companies identify the environmental impact of their products from raw material sourcing to disposal. By understanding the entire life cycle of their products, companies can make more informed decisions about where to focus their sustainability efforts. LCAs can help pinpoint opportunities to reduce resource consumption, minimize waste, and lower emissions throughout the supply chain.

Regulatory compliance and voluntary standards: Sustainability efforts are increasingly being shaped by regulatory frameworks such as the European Union’s Green Deal and the United Nations' Sustainable Development Goals (SDGs). Beyond compliance, pharmaceutical companies are voluntarily adhering to standards such as the Pharmaceutical Supply Chain Initiative (PSCI), which focuses on environmental responsibility, labor rights, health, and safety. These standards help guide sustainable development and set benchmarks for environmental performance.

Conclusion

The pharmaceutical sector is at a critical juncture, where environmental sustainability is no longer an option but a necessity. As the industry continues to grow, adopting environmentally conscious chemistry and meeting sustainability benchmarks are essential to mitigating its environmental impact. Green chemistry principles provide the foundation for sustainable drug manufacturing, while benchmarks like carbon neutrality, waste reduction, and water stewardship guide the sector toward a greener future. Ultimately, collaboration between pharmaceutical companies, regulatory bodies, and stakeholders will be key to achieving long-term sustainability goals. By embracing innovation and committing to environmentally conscious practices, the pharmaceutical industry can contribute to global health while ensuring a healthier planet for future generations.

References

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. J Nurs 32: 1335-1343.

Indexed at, Google Scholar, Crossref

2. Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA (2018) Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. Pharmacoepidemiol Drug Saf 27: 1053-1059.

Indexed at, Google Scholar, Crossref

3. Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE, et al. (2021) Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series. Am J Emerg Med 44: 11-13.

Indexed at, Google Scholar, Crossref

4. Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, et al. (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50: 335-344.

Indexed at, Google Scholar, Crossref

5. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui L, et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord 19: 144.

Indexed at, Google Scholar, Crossref

6. Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, et al. (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40.

Indexed at, Google Scholar, Crossref

7. Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ.

Indexed at, Google Scholar, Crossref

8. Nikouline A, Brzozowski M (2021) New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report. CJEM 23: 712-714.

Indexed at, Google Scholar, Crossref

9. Maamari J, Yeung SCJ, Chaftari PS (2019) Diabetic ketoacidosis induced by a single dose of pembrolizumab. Pharmacoepidemiol Drug Saf 37: 376.

Indexed at, Google Scholar, Crossref

10. Mae S, Kuriyama A, Tachibana H (2021) Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med 60: 342-344.

Indexed at, Google Scholar, Crossref